Topiramate extended-release - Supernus Pharmaceuticals

Drug Profile

Topiramate extended-release - Supernus Pharmaceuticals

Alternative Names: SPN-538; Topiramate controlled-release - Supernus Pharmaceuticals; TPM XR; Trokendi XR; Trokesa

Latest Information Update: 19 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Epilepsy; Migraine

Most Recent Events

  • 09 May 2017 Launched for Migraine (Prevention) in USA (PO)
  • 05 Apr 2017 Registered for Migraine (Prevention) in USA (PO)
  • 07 Mar 2017 Supernus Pharmaceuticals enters into binding term sheet with Actavis Laboratories related to patent dispute of generic topiramate extended release in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top